Nothing Special   »   [go: up one dir, main page]

MX2012004157A - 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc. - Google Patents

8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.

Info

Publication number
MX2012004157A
MX2012004157A MX2012004157A MX2012004157A MX2012004157A MX 2012004157 A MX2012004157 A MX 2012004157A MX 2012004157 A MX2012004157 A MX 2012004157A MX 2012004157 A MX2012004157 A MX 2012004157A MX 2012004157 A MX2012004157 A MX 2012004157A
Authority
MX
Mexico
Prior art keywords
treatment
pyrido
pyrimidin
aryl
ones
Prior art date
Application number
MX2012004157A
Other languages
English (en)
Inventor
Benedikt Vollrath
Sergio G Duron
David Campbell
Warren Wade
Original Assignee
Afraxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afraxis Inc filed Critical Afraxis Inc
Publication of MX2012004157A publication Critical patent/MX2012004157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proveen aquí inhibidores de PAK y métodos de utilización de inhibidores de PAK para el tratamiento de trastornos del sistema nervioso central tales como trastornos neurosiquiátricos.
MX2012004157A 2009-10-09 2010-10-08 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc. MX2012004157A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25026209P 2009-10-09 2009-10-09
US35305410P 2010-06-09 2010-06-09
PCT/US2010/052106 WO2011044535A2 (en) 2009-10-09 2010-10-08 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
MX2012004157A true MX2012004157A (es) 2012-08-03

Family

ID=43857425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004157A MX2012004157A (es) 2009-10-09 2010-10-08 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.

Country Status (15)

Country Link
US (2) US8372970B2 (es)
EP (1) EP2486037A4 (es)
JP (1) JP2013507395A (es)
KR (1) KR20120104200A (es)
CN (1) CN102648200A (es)
AR (1) AR078609A1 (es)
AU (1) AU2010303218A1 (es)
BR (1) BR112012007935A2 (es)
CA (1) CA2776770A1 (es)
EA (1) EA201270498A1 (es)
IL (1) IL219078A0 (es)
MX (1) MX2012004157A (es)
TW (1) TW201118095A (es)
WO (1) WO2011044535A2 (es)
ZA (1) ZA201202688B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20110217280A1 (en) * 2007-12-19 2011-09-08 Vollrath Benedikt Methods for treating neuropsychiatric conditions
WO2009086204A2 (en) * 2007-12-21 2009-07-09 Afraxis, Inc. Methods for treating neuropsychiatric conditions
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
WO2011063415A2 (en) * 2009-11-23 2011-05-26 Afraxis, Inc. Methods for treating mild cognitive impairment
KR101698250B1 (ko) 2010-05-17 2017-01-19 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
US8912203B2 (en) 2010-06-09 2014-12-16 Afraxis Holdings, Inc. 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
WO2011159945A2 (en) * 2010-06-16 2011-12-22 Afraxis, Inc. Methods for treating neurological conditions
JP2014513079A (ja) * 2011-04-08 2014-05-29 アフラクシス・ホールディングス・インコーポレイテッド 神経系疾患及び癌の治療のための８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
WO2013067434A1 (en) * 2011-11-04 2013-05-10 Afraxis, Inc. Pak inhibitors for the treatment of fragile x syndrome
CN104168898A (zh) 2012-03-16 2014-11-26 霍夫曼-拉罗奇有限公司 以pak1抑制剂治疗黑色素瘤的方法
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
WO2014056082A1 (en) * 2012-10-12 2014-04-17 University Of Prince Edward Island Method for measuring symptoms of autism spectrum disorders and comorbid conditions
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
WO2014127112A1 (en) * 2013-02-13 2014-08-21 Baylor College Of Medicine Memory enhancer and actin dynamics
WO2015011252A1 (en) * 2013-07-26 2015-01-29 F. Hoffmann-La Roche Ag Pyrimidine-pyridinone serine/threonine kinase inhibitors
EP2905024A1 (en) 2014-02-07 2015-08-12 Institut Quimic De Sarriá Cets, Fundació Privada Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae
CN105294682B (zh) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
TWI511868B (zh) * 2014-10-27 2015-12-11 Nat Univ Tsing Hua A Method for Instantaneous Measurement of Local Permeability Coefficient of Injection Molding
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
US11065251B2 (en) 2016-05-06 2021-07-20 Albert Einstein College Of Medicine PAK1 inhibitors and uses thereof
CA3205784A1 (en) 2017-01-20 2018-07-26 Polaris Industries Inc. Diagnostic systems and methods of a continuously variable transmission
CN108191857B (zh) * 2017-01-24 2020-10-23 晟科药业（江苏）有限公司 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
CN110914267B (zh) * 2017-07-19 2022-07-12 江苏奥赛康药业有限公司 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用
CN109813912B (zh) * 2019-01-04 2021-12-28 深圳大学 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
WO2021108803A1 (en) 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
CN116271206A (zh) * 2023-04-10 2023-06-23 温州市工业科学研究院 一种镓卟啉配合物/丝素蛋白抗菌敷料及其制作方法
CN118084902B (zh) * 2024-01-16 2024-10-29 赣南师范大学 2-氨基噻唑嘧啶并吡啶酮类化合物或药学上可接受的盐或立体异构体及制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
AU2439701A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Novel heterocycles
AU2001233028A1 (en) * 2000-03-06 2001-10-03 Warner-Lambert Company 5-alkylpyrido(2,3-D)pyrimidines tyrosine kinase inhibitors
WO2001098775A1 (en) * 2000-06-16 2001-12-27 The Board Of Trustees Of The University Of Arkansas Regulation of the p21 gene and uses thereof
ES2243568T3 (es) * 2000-08-31 2005-12-01 F. Hoffmann-La Roche Ag 7-oxo-piridopirimidinas.
ATE305303T1 (de) * 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
MXPA04005939A (es) * 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
JP4758349B2 (ja) 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
CA2555724A1 (en) * 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US20090036472A1 (en) 2005-02-02 2009-02-05 Palle Venkata P Azabicyclo derivatives as anti-inflammatory agents
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2076513A1 (en) 2006-10-20 2009-07-08 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions

Also Published As

Publication number Publication date
CA2776770A1 (en) 2011-04-14
WO2011044535A3 (en) 2011-08-18
JP2013507395A (ja) 2013-03-04
EA201270498A1 (ru) 2012-11-30
AU2010303218A1 (en) 2012-05-10
US20130035335A1 (en) 2013-02-07
TW201118095A (en) 2011-06-01
CN102648200A (zh) 2012-08-22
KR20120104200A (ko) 2012-09-20
EP2486037A4 (en) 2013-01-16
US8372970B2 (en) 2013-02-12
BR112012007935A2 (pt) 2019-09-24
WO2011044535A2 (en) 2011-04-14
US20120270866A1 (en) 2012-10-25
ZA201202688B (en) 2014-10-29
EP2486037A2 (en) 2012-08-15
IL219078A0 (en) 2012-06-28
AR078609A1 (es) 2011-11-23

Similar Documents

Publication Publication Date Title
MX2012004157A (es) 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.
MX2013011518A (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer.
EP2580214A4 (en) 8- (SULFONYLARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
EP2580213A4 (en) 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
WO2011156780A3 (en) 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156786A3 (en) 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156775A3 (en) 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
ZA201306348B (en) Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
SI2609082T1 (sl) Imidazo(4,5-c)kinolini kot inhibitorji dna-pk
MX357502B (es) Derivados de pirrolotriazinona.
HK1139948A1 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
GEP20156333B (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
IL201209A0 (en) Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
HRP20182021T1 (hr) Derivati [1,2,4]triazolo[1,5-a]pirimidina kao inhibitori proteazoma protozoe za liječenje parazitskih bolesti poput lišmenijaze
HK1177207A1 (en) 5-oxo-5, 8-dihydropyrido [2, 3-d]pyrimidine derivatives as camkii kinases inhibitors for the treatment of cardiovascular diseases camkii 5--58-[23-d]
EA201390620A1 (ru) ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
NZ621597A (en) Triazolopyridine compounds as pde10a inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal